PMID- 27456750
OWN - NLM
STAT- MEDLINE
DCOM- 20170802
LR  - 20240229
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 70
IP  - 8
DP  - 2016 Aug
TI  - Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists 
      compared with exenatide and liraglutide in type 2 diabetes: a systemic review of 
      randomised controlled trials.
PG  - 649-56
LID - 10.1111/ijcp.12847 [doi]
AB  - BACKGROUND: Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) have 
      shown promising results in the treatment of type 2 diabetes. Herein, we compared 
      the efficacy and safety of once-weekly GLP-1RAs with exenatide and liraglutide 
      separately. METHODS: We systematically surveyed the pertinent literature using 
      various databases. The randomised controlled trials that compared once-weekly 
      GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included. Our 
      main end-points were control of glycaemia, body weight, hypoglycaemia and 
      gastrointestinal adverse events (AEs). RESULTS: Our analysis included eight 
      trials involving 5531 patients. Exenatide-long-acting release (LAR), dulaglutide 
      and taspoglutide were more effective than twice-daily exenatide in reducing 
      glycosylated haemoglobin A1c (HbA1c) and fasting blood glucose (FBG) levels and 
      achieving HbA1c targets (< 7.0% and </= 6.5%). Liraglutide was as effective as 
      dulaglutide and more effective than exenatide-LAR and albiglutide in controlling 
      glycaemia. With regard to the effectiveness in decreasing body weight, 
      exenatide-LAR, dulaglutide and taspoglutide were similar to exenatide whereas 
      exenatide-LAR, dulaglutide and albiglutide were inferior to liraglutide. 
      Once-weekly GLP-1RAs, exenatide and liraglutide resulted in a similar incidence 
      of hypoglycaemia and of gastrointestinal, serious, or other AEs. CONCLUSIONS: 
      Once-weekly GLP-1RAs were more effective in controlling glycaemia and equally 
      effective in decreasing body weight than twice-daily exenatide but were inferior 
      to liraglutide in controlling these two parameters (dulaglutide was similar with 
      liraglutide in controlling glycaemia). Once-weekly GLP-1RAs, exenatide and 
      liraglutide had a similar risk of causing AEs.
CI  - (c) 2016 John Wiley & Sons Ltd.
FAU - Xue, X
AU  - Xue X
AD  - Department of Endocrinology, Tengzhou Central People's Hospital, Shandong, China.
FAU - Ren, Z
AU  - Ren Z
AD  - Department of Endocrinology, Tengzhou Central People's Hospital, Shandong, China.
FAU - Zhang, A
AU  - Zhang A
AD  - Zaozhuang Science and Technology College, Shandong, China.
FAU - Yang, Q
AU  - Yang Q
AD  - Department of Medicine, Maternal and Child Care Service Centre of Tengzhou City, 
      Shandong, China.
FAU - Zhang, W
AU  - Zhang W
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine II, 
      University Hospital of Freiburg, Freiburg, Germany.
FAU - Liu, F
AU  - Liu F
AD  - Department of Endocrinology, Tengzhou Central People's Hospital, Shandong, China.
AD  - Division of Endocrinology and Diabetology, Department of Internal Medicine II, 
      University Hospital of Freiburg, Freiburg, Germany.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20160725
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - WTT295HSY5 (dulaglutide)
RN  - 9P1872D4OL (Exenatide)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 839I73S42A (Liraglutide)
RN  - 0 (Peptides)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 2PHK27IP3B (taspoglutide)
RN  - 0 (Venoms)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Drug Administration Schedule
MH  - Exenatide
MH  - Gastrointestinal Diseases/chemically induced
MH  - *Glucagon-Like Peptide-1 Receptor/agonists
MH  - Glucagon-Like Peptides/administration & dosage/adverse effects/analogs & 
      derivatives
MH  - Glycated Hemoglobin/metabolism
MH  - Hypoglycemia/chemically induced
MH  - *Hypoglycemic Agents/administration & dosage/adverse effects
MH  - Immunoglobulin Fc Fragments/administration & dosage/adverse effects
MH  - *Liraglutide/administration & dosage/adverse effects
MH  - *Peptides/administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Recombinant Fusion Proteins/administration & dosage/adverse effects
MH  - Risk Factors
MH  - Treatment Outcome
MH  - *Venoms/administration & dosage/adverse effects
MH  - Weight Loss/drug effects
EDAT- 2016/07/28 06:00
MHDA- 2017/08/02 06:00
CRDT- 2016/07/27 06:00
PHST- 2016/07/27 06:00 [entrez]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
AID - 10.1111/ijcp.12847 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2016 Aug;70(8):649-56. doi: 10.1111/ijcp.12847. Epub 2016 Jul 
      25.